Literature DB >> 17488676

Increased MDM2 expression is associated with inferior survival in mantle-cell lymphoma, but not related to the MDM2 SNP309.

Elena Hartmann, Verònica Fernàndez, Heike Stoecklein, Luis Hernández, Elías Campo, Andreas Rosenwald.   

Abstract

We here show that increased expression of MDM2, a negative regulator of p53, correlates with inferior survival in a series of 43 mantle cell lymphomas. MDM2 overexpression is associated with copy number gains of the MDM2 locus in single tumors, but not with the recently reported MDM2 promoter SNP309.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17488676     DOI： 10.3324/haematol.10891

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  7 in total

Review 1.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

2.  HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.

Authors:  Richard J Jones; Veerabhadran Baladandayuthapani; Sattva Neelapu; Luis E Fayad; Jorge E Romaguera; Michael Wang; Rakesh Sharma; Dajun Yang; Robert Z Orlowski
Journal:  Blood       Date:  2011-08-15       Impact factor: 22.113

Review 3.  Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.

Authors:  Kevin Wang; Xiangao Huang; Maurizio Di Liberto; Selina Chen-Kiang
Journal:  Hematol Oncol Clin North Am       Date:  2020-08-01       Impact factor: 3.722

4.  MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.

Authors:  Zijun Y Xu-Monette; Michael B Møller; Alexander Tzankov; Santiago Montes-Moreno; Wenwei Hu; Ganiraju C Manyam; Louise Kristensen; Lei Fan; Carlo Visco; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Lin Wu; Xiaoying Zhao; Carlos E Bueso-Ramos; Sa A Wang; Ronald S Go; Yong Li; Jane N Winter; Miguel A Piris; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-08-27       Impact factor: 22.113

Review 5.  Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.

Authors:  Sean M Post; Vinod Pant; Hussein Abbas; Alfonso Quintás-Cardama
Journal:  Oncotarget       Date:  2010-07

Review 6.  Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment.

Authors:  Roman Hrstka; Philip J Coates; Borivoj Vojtesek
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

Review 7.  MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.

Authors:  Veronica Tisato; Rebecca Voltan; Arianna Gonelli; Paola Secchiero; Giorgio Zauli
Journal:  J Hematol Oncol       Date:  2017-07-03       Impact factor: 17.388
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.